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Purpose: Erythropoietin (EPO) is a renal cytokine that is primarily involved in
hematopoiesis while also playing a role in non-hematopoietic tissues expressing the
EPO-receptor (EPOR). The EPOR is present in human skeletal muscle. In mouse skeletal
muscle, EPO stimulation can activate the AKT serine/threonine kinase 1 (AKT) signaling
pathway, the main positive regulator of muscle protein synthesis. We hypothesized that a
single intravenous EPO injection combined with acute resistance exercise would have a
synergistic effect on skeletal muscle protein synthesis via activation of the AKT pathway.
Methods: Ten young (24.2± 0.9 years) and 10 older (66.6± 1.1 years) healthy subjects
received a primed, constant infusion of [ring-13C
6] L-phenylalanine and a single injection
of 10,000 IU epoetin-beta or placebo in a double-blind randomized, cross-over design.
2 h after the injection, the subjects completed an acute bout of leg extension resistance
exercise to stimulate skeletal muscle protein synthesis.
Results: Significant interaction effects in the phosphorylation levels of the members of
the AKT signaling pathway indicated a differential activation of protein synthesis signaling
in older subjects when compared to young subjects. However, EPO offered no synergistic
effect on vastus lateralis mixed muscle protein synthesis rate in young or older subjects.
Conclusions: Despite its ability to activate the AKT pathway in skeletal muscle, an acute
EPO injection had no additive or synergistic effect on the exercise-induced activation of
muscle protein synthesis or muscle protein synthesis signaling pathways.
Keywords: aging, anabolic signaling, erythropoietin, muscle protein synthesis, resistance exercise
INTRODUCTION
Erythropoietin (EPO) is a glycoproteic hormone that is primarily synthetized in the peritubular
fibroblast-like cells of the renal cortex (Maxwell et al., 1993, 1997). EPO is produced in response
to tissue hypoxia; a process that results in a larger number of circulating erythrocytes and a
better oxygenation of the active tissues (Jelkmann, 2004, 2011; Noguchi et al., 2008). Beyond
EPO’s regulatory function in haematopoiesis and well documented abuse by endurance athletes
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(Lamon et al., 2010), the EPO-receptor (EPOR) is expressed in
several other tissues including endothelial, neural, cardiovascular
and muscle tissue (Noguchi et al., 2008). EPO plays various
roles in extra-hematopoietic tissues, including protection against
oxidative stress (Zaman et al., 1999) and neovascularization
(Yasuda et al., 1998). As the EPOmolecule binds to its receptor, it
induces a conformational change that activates the EPOR (Miura
et al., 1991; Dusanter-Fourt et al., 1992) via the phosphorylation
of the JAK2 protein (Constantinescu et al., 1999; Remy et al.,
1999). EPOR activation in turn triggers STAT5 phosphorylation,
which enters the nucleus and activates the transcription of
a subset of EPO target genes (Damen et al., 1995; Pallard
et al., 1995; Penta and Sawyer, 1995; Klingmuller et al., 1996;
Quelle et al., 1996). Alternatively, in interleukin-3-dependent cell
lines characterized by high levels of EPOR, EPO-induced JAK2
activation also appears to regulate the phosphatidylinositol 3-
kinase (PI3)/AKT (AKT) pathway and the Ras/mitogen-activated
kinase (MAPK) signaling pathway (Damen et al., 1993; Miura
et al., 1994; Constantinescu et al., 1999; Fisher, 2003). In addition,
EPO can activate AKT in extra-hematopoietic tissues including
cardiomyocytes (Tramontano et al., 2003), endothelial cells
(Elayappan et al., 2009) as well as in the skeletal muscle of mouse
overexpressing the EPO protein (Hojman et al., 2009).
The EPOR protein is expressed in human skeletal muscle
tissue (Lamon et al., 2014). Skeletal muscle accounts for about
40% of human body mass, houses 50–75% of the body’s total
protein pool, and is dynamically regulated by the balance
between muscle protein synthesis and degradation (Eley and
Tisdale, 2007). Maintaining this equilibrium is critical to prevent
muscle atrophy and to preserve metabolic health (Rasmussen
and Phillips, 2003). However, by the age of 50, age-related
muscle wasting can claim as much as 10% of an adult’s muscle
mass, with a further average reduction of 1% per year thereafter
(Dorrens and Rennie, 2003; Phillips, 2012). AKT signaling is
an important molecular switch that positively regulates skeletal
muscle hypertrophy in myotubes (Rommel et al., 2001) and
human muscle tissue (Léger et al., 2006; Sandri et al., 2013;
Schiaffino et al., 2013) by enhancing protein synthesis and
inhibiting protein degradation pathways. AKT signaling can be
activated by various cellular signals including resistance exercise
(Léger et al., 2006), a potent anabolic stimulus that promotes
muscle protein synthesis and hypertrophy (Marcotte et al., 2015).
This anabolic response to resistance exercise is often attenuated
in the elderly, who also display reduced phosphorylation of
the members of the AKT signaling pathway following exercise
(Dennis et al., 2008; Kumar et al., 2009).
Several studies have examined changes in human muscle
tissue following acute or chronic systemic injection of
recombinant human EPO. A single systemic injection of
EPO increased the mRNA levels of the myogenic regulatory
factor MYF6 (formerly MRF-4) 10 h after injection (Lundby
et al., 2008b), suggesting a role for EPO and its receptor in muscle
development or remodeling. These findings were supported
by a recent study showing that 10 weeks of EPO treatment
increased PAX7 and MYOD1 content in human satellite cells
(Hoedt et al., 2015). An early study on patients with chronic
renal failure treated with EPO reported an increase in type I
muscle fiber diameter and in muscle glycogen content when
compared to baseline levels (Davenport et al., 1993). Finally,
muscle mitochondrial oxidative phosphorylation and maximal
electron chain transport capacity were enhanced following
8 weeks of EPO treatment in healthy humans (Plenge et al.,
2012).
Previous studies have shown that EPO can activate AKT
in extra-hematopoietic tissues, including mouse skeletal muscle
(Hojman et al., 2009). We hypothesize that a single EPO
injection, when combined with acute resistance exercise, will
have a synergistic effect on the exercise-induced activation of
muscle protein synthesis by activating the AKT pathway in
human skeletal muscle. A secondary hypothesis is that if EPO
triggers an anabolic response in skeletal muscle, it may be able
to rescue a potential reduction in exercise-induced activation of
protein synthesis in the older participants.
MATERIALS AND METHODS
Subjects
Subject characteristics have been previously described (Stefanetti
et al., 2014). Briefly, 10 healthy young (18–30 years old)
and 10 healthy older (60–75 years old) males gave their
informed consent to participate in the study and agreed
to muscle biopsies, physiological testing, and anthropometric
measurements. The subjects were physically active but had
not participated in a resistance training program or regularly
consumed protein supplements for at least 6 months. No
subject had a history of anabolic hormone use. The study was
approved by the Deakin University Human Research Committee
(#2011-043) in accordance to the Declaration of Helsinki (2008)
(http://www.wma.net/en/30publications/10policies/b3/).
Experimental Design
Subjects abstained from strenuous exercise, caffeine and alcohol
consumption for 24 h prior to the trial. On the night before
the trial, the subjects consumed a standardized meal containing
20% fat, 14% protein and 66% carbohydrate. After an overnight
fast, the subjects reported to the laboratory at 7 a.m. An 18-
gauge cannulae was inserted into the antecubital vein of their
left arm for blood sampling and for the injection of 10,000
IU recombinant human EPO (Recormon R©, epoetin beta, Roche
Pharmaceuticals, Dee Why, NSW) or a saline control (placebo)
in a double-blind randomized, cross-over design. This dose
represents a compromise between the doses administered to
treat patients with renal insufficiencies and the doses reported
in doping practices. Another cannulae was inserted in their
right arm for a 5 h primed (0.34 mg/kg), continuous infusion
of [ring-13C6] L-phenylalanine (0.0085 mg/kg/min; Cambridge
Isotope Laboratories, Tewksbury, MA). The subjects rested in
the supine position for 2 h prior to the sampling of the 1st
muscle biopsy. Biopsies were obtained from the vastus lateralis
muscle using 5 mm Bergstrom needle and standard technique, as
previously described (Stefanetti et al., 2014). Immediately after
the muscle biopsy, subjects completed a 3-min light cycling
warm-up followed by an acute bout of 2-leg extension exercise.
The exercise protocol consisted of 3 sets of 14 repetitions at
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FIGURE 1 | Experimental timeline of the study. At time 0, the subjects received a 10,000 IU intra-venous injection of epoetin beta (Recormon®) or a placebo. The
exercise bout consisted of 3 sets of 14 repetitions of a leg press exercise at an intensity of 60% of the individual 1 repetition maximum (1RM). Muscle biopsies were
collected before and 2 h after exercise. Venous blood samples were collected every 30 min for the whole duration of the study.
60% of maximal voluntary contraction (60% 1 RM) with 2-min
recovery between sets. The subjects then completed a 3-min light
cycling cool-down, and remained supine and at rest thereafter.
2 h post-exercise, a second muscle biopsy was taken from the
contralateral leg to avoid any local effect of the pre-exercise
biopsy. Venous blood samples were collected every 30 min for a 5
h period. Figure 1 depicts the experimental timeline of the study.
A minimum of 4 weeks after the trial, the subjects returned to the
laboratory and repeated the experiment but this time swapping
the treatment for either EPO or the saline control. Dual-Energy
X-Ray (DXA) Absorptiometry Scan (Lunar Prodigy, GE Lunar
Corp., Madison, WI) was used to assess total body composition,
regional (arms and legs) body composition (lean mass, fat mass
and percentage body fat), as well as lumbar spine (L1–L4) and
proximal femur (femoral neck and total hip) areal bone density.
Preliminary testing procedures have been described elsewhere
(Stefanetti et al., 2014).
Protein Extraction and Western Blotting
The protein extraction and western blotting methods have
been described elsewhere (Stefanetti et al., 2014) with the
following modifications. Equal amount of protein was separated
on a 4–12% NuPAGE R© Novex Bis-Tris Gel (Life Technologies,
Mulgrave, VIC) in NuPAGE R© SDS MOPS Running Buffer
(Life Technologies) and then transferred onto Immobilon
TM−FL
PVDF membranes (Millipore, Billerica, MA). For phospho-
GSK-3β, equal amount of protein was diluted using a 3X
SDS solution separated and run on 18-well 4–12% gradient
Criterion SDS-PAGE gels (Bio-Rad Laboratories, Hercules, CA)
and then transferred onto Immobilon
TM−P PVDF membranes
(Millipore). All membranes where then blocked in 5% BSA/PBS.
Membranes were incubated at 4◦C in the following primary
antibodies diluted 1:1000 in 5% BSA/PBS: phospho-AKTSer473
(CS #9271), phospho-4E-BP1Thr37/46 (CS #2855), phospho-
p70-S6KThr389 (CS #9234), phospho-p44/42MAPKThr202/Tyr204
(CS #9101), phospho-GSK-3βSer9 (CS #9336; Cell Signaling
Technologies, Arundel, QLD). Following overnight incubation,
the membranes were washed and incubated for 1 h with a goat
anti-rabbit IgG antibody labeled with an infrared-fluorescent 800
nm dye (Alexa Fluor R© 800, Life Technologies) diluted 1:10,000
in a buffer containing PBS and Odyssey R© blocking buffer (LI-
COR Biosciences, Lincoln, NE) at a 1:1 ratio and 0.01% SDS or
an anti-rabbit IgG (H+L) DyLight
TM
800 Conjugate (Genesearch
diluted 1:10,000 in a buffer containing 5% BSA. After washing,
the proteins were exposed on an Odyssey R© Infrared Imaging
System (LI-COR Biosciences) and individual protein band
optical densities were determined using the Odyssey R© Infrared
Imaging System software. All blots were normalized to the
GAPDH protein (G8795; Sigma-Aldrich, Sydney, NSW). For
phospho-GSK-3β, the proteins were exposed on a Gel Doc
TM
imaging system (Bio-Rad Laboratories). Individual protein band
optical densities were determined using the Image Lab software
(Bio-Rad Laboratories) and all blots were normalized to the total
protein load.
Isotopic Enrichment in Plasma
Venous blood samples were collected in heparin-tubes, manually
inverted and immediately centrifuged for 15 min at 13,000
RPM at 4◦C. The supernatant (plasma) was then isolated
and frozen at −80◦C for further analysis. After thawing,
plasma was precipitated using an equal volume of 15%
sulfosalicylic acid (SSA) solution and centrifuged for 20 min at
13,000 RPM at 4◦C. Blood amino acids were extracted from
500 mL of supernatant by cation exchange chromatography
(Dowex AG 50W–8X, 100–200 mesh H+ form; Bio-Rad
Laboratories). Phenylalanine enrichments were determined by
gas chromatography–mass spectrometry (GC–MS) using the
tertbutyldimethylsilyl derivative with electron impact ionization
as described previously (Freischmidt et al., 2015). Ions 336 and
342 were monitored.
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Isotopic Enrichment in Muscle Proteins
A 30mg piece of muscle biopsy was used for isolation of
mixed muscle bound (myofibrillar) and intracellular protein
fractions. Briefly, bound muscle proteins were extracted in
perchloric acid and hydrolysed using 6N hydrochloric acid
(110◦C for 24 h). Isotopic enrichments of [ring-13C
6]-L-
phenylalanine in tissue fluid (intracellular fraction) were used as
a precursor pool for the calculation of the fractional synthesis
rate (FSR). Total muscle phenylalanine was isolated using cation
exchange chromatography (50W-8X, 200–400 mesh H+ form;
Bio-Rad Laboratories). Amino acids were eluted in 8 mL of
2N ammonium hydroxide and dried under vacuum. Muscle
intracellular and bound protein [ring-13C
6]-L-phenylalanine
enrichments were determined by GC-MS with electron impact
ionization using the tert-butyldimethylsilyl derivative. Ions 238
and 240 were monitored for bound protein enrichments; ions
336 and 342 were monitored for intracellular enrichments
as described previously (Freischmidt et al., 2015). Mixed
muscle protein FSR (%/h) was calculated by measuring the
direct incorporation of [ring-13C
6]-L-phenylalanine by using the
precursor-product model (Chang et al., 2010; Mei et al., 2012;
Mestdagh et al., 2014):
FSR =
EP2− EP1
(Emx t)
x 60 x 100
where EP1 and EP2 are the bound enrichments of [ring-
13C
6]-L-phenylalanine for the two muscle biopsies, Em is the
mean enrichment of [ring-13C
6]-L-phenylalanine in the muscle
intracellular pool, and t is the time interval (min) between the
two biopsies.
Statistical Methods
All data are reported as mean ± SEM. Paired t-tests or the
mixed-model 2-way analysis of variance (ANOVA) were used to
compare group means. Diagnostic plots of residuals and fitted
values were checked to ensure homogeneity of variance (a key
assumption for ANOVA). Consequently, all protein expression
data was log10-transformed and analyses were conducted on
these transformed scales. The least significant difference (LSD)
test was used to compare pairs of means. The significance levels
for the F-tests in the t-tests and ANOVA and the LSD tests were
set at p < 0.05.
RESULTS
Subjects’ Demographics
Subjects’ demographics has been reported in a previously
published manuscript (Stefanetti et al., 2014). Briefly, the two
subject groups were respectively aged 24.2 ± 0.9 y.o. and 66.6
± 1.1 y.o. and presented no significant difference in body mass
(young: 73.8 ± 3.6 kg, older: 83.4 ± 7.1 kg), fat mass (young:
13.6 ± 2.7 kg, older: 19.5 ± 3.9 kg), lean mass (young: 57.9 ±
1.9 kg, older: 60.2 ± 3.3 kg), lean/total body mass ratio (young:
0.8± 0.02, older: 0.7± 0.02) and maximal voluntary contraction
(1RM; young: 98.2± 7.0 kg, older: 80.9± 7.2 kg).
Muscle Protein Synthesis
Subjects remained in isotopic steady-state throughout the
infusion protocol, with no difference due to EPO treatment
(Figure 2). EPO treatment did not influence FSR in young or
older subjects. The average FSR for all subjects was 0.08% per
hour and no difference existed between young and older subjects
(Figure 3).
Protein Expression of the Members of the
Protein Synthesis Pathways
The phosphorylation levels of the members of the AKT and
the MAPK signaling pathways were measured in muscle tissue
obtained pre- and post-exercise. As no difference was detected
between the two treatment groups (EPO vs. placebo) for any of
the measured targets, the protein data were pooled for further
analysis. Two hour following exercise, there was a main effect of
exercise on AKT phosphorylation levels (p < 0.05; Figure 4A).
It should however be noticed that, when individual t-tests were
run, this difference appeared significant in the young cohort
FIGURE 2 | Plasma enrichment of [ring-13C6] L-phenylalanine during
the study; enrichments were averaged within age groups. EPO, n = 6;
Placebo, n = 6.
FIGURE 3 | Mixed muscle fractional synthesis rate measured in young
(24.2 ± 0.9 y.o.) and older (66.6 ± 1.1 y.o.) subjects between 0 and 2 h
post exercise. There was no significant difference due to treatment, age or a
combination of both factors.
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FIGURE 4 | Activation of the members of the protein synthesis signaling pathways with exercise in muscle from young and older subjects. (A).
Representative immunoblots of phospho-AKTSer473 and corresponding quantification. There was a significant main effect of exercise (p = 0.0139).
(B). Representative immunoblots of phospho-4E-BP1Thr37/46 and corresponding quantification. There was a significant age × exercise interaction (p = 0.0206). (C).
Representative immunoblots of phospho-p70-S6KThr389 and corresponding quantification. There was a significant age x exercise interaction (p < 0.0397). (D).
Representative immunoblots of phospho-GSK3BSer9 and corresponding quantification. (E). Representative immunoblots of phospho-p44/42 MAPK Thr202/Tyr204
and corresponding quantification. Note that non-contiguous gel lanes are demarcated by white spaces; no adjustment to digital images do alter the information
contained therein.
only (Zacharewicz et al., 2014). No main effect of exercise was
detected in the protein levels of phospho-p70-S6K and phospho-
4E-BP1, however an age x exercise interaction was apparent for
both (p < 0.05; Figures 4B,C). Associated post-hoc tests were
not significant. Finally, no change due to age or exercise was
observed on phospho-GSK3B or phospho-p44/42MAPK protein
levels (Figures 4D,E).
DISCUSSION
Resistance exercise is a potent activator of anabolic pathways
in skeletal muscle (Marcotte et al., 2015). Here we investigated
for the first time the effect of an acute systemic EPO injection
on muscle protein synthesis following a single protein synthesis
stimulating exercise bout. We hypothesized that EPO may
require a concurrent anabolic stimulus to exert its effects in
muscle and as a result, that exercise and EPO may have a
synergistic effect on muscle protein synthesis. However, we
report that a single EPO injection does not alter muscle protein
synthesis rates or signaling following an acute resistance exercise
bout in young or older subjects.
Our study is the first to evaluate the potential synergistic
effect of acute exercise and EPO on human skeletal muscle
FSR. Christensen et al. (2012b) have previously evaluated the
effects of a single systemic injection of 400 IU/kg EPO on whole
body and forearm protein metabolism, measured as carbamide,
phenylalanine, and tyrosine fluxes, in young males in a resting
situation only. These authors reported no effect of EPO injection
on whole body and forearm protein turnover at rest. Another
study showed that EPO treatment increased type I muscle fiber
diameter in patients with chronic renal failure when compared to
pre-treatment levels (Davenport et al., 1993), although 14 weeks
of EPO treatment had no effect on muscle fiber hypertrophy in
young males (Lundby et al., 2008a). A positive effect of EPO
on muscle hypertrophy was however supported by rodent data
showing that, in a mouse model where the Epo gene was electro
transferred, resulting in supra-physiological EPO levels, mice
displayed significant leg muscle hypertrophy when compared
to their contralateral non-transfected leg and to control mice
(Hojman et al., 2009). Taken together, these results suggest
that extra-physiological levels of EPO, achieved by long-term
high-dose treatment or gene modification, may be necessary to
observe an effect of EPO on skeletal muscle protein accretion and
hypertrophy.
The mixed muscle FSR we observed 2 h following a bout
of resistance exercise were consistent with the values obtained
1-and 2-h following a similar exercise regime (Kumar et al.,
2009). No effect of age was observed. An average lower protein
synthesis response in elderly subjects when compared to younger
subjects has only been observed when measured 1–2 h post-
exercise (average response to 60–90% 1RM intensities), but no
difference was reported when measured 0–1 h post-exercise. In
addition, no breakdown of the response induced by the different
exercise intensities was provided, suggesting that an age effect
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may only occur at higher exercise intensities (Kumar et al., 2009).
In addition, Fry et al. did not report any effect of age when FSR
was measured 0–3 h post a resistance exercise bout consisting of
eight sets of 10 repetitions at 70% 1RM, leading to the hypothesis
that a decrease in protein synthesis activation in older subjects
may only be observed after a certain time delay (Fry et al., 2011).
Upstream from the protein synthesis process itself, the
phosphorylation levels of the AKT protein significantly increased
2 h post-exercise when compared to baseline. In addition, there
was a combined effect of age and exercise on the phosphorylation
levels of the p70-S6K and 4E-BP1 proteins suggesting that muscle
protein synthesis signaling is impaired in older when compared
to young subjects (Dennis et al., 2008; Kumar et al., 2009),
although this may only translate to the FSR at a later time
point. While post-hoc tests did not reveal significant differences
within age group means for phospho-p70-S6K and phospho-
4E-BP1, this might be indicative of these proteins returning
to their baseline levels 2 h post-exercise. Failure to observe
phosphorylation changes in p70-S6K and 4E-BP1 2 h following
resistance exercise has been reported before, independent of
protein synthesis activation (Kumar et al., 2009). Of interest,
in a previous publication we reported no age-related difference
in the regulation of the members of the ubiquitin proteasome
pathway following exercise in the same cohort (Stefanetti et al.,
2014), suggesting that in contrast to protein synthesis, protein
degradation signaling is not affected by age.
Consistent with the lack of effect on muscle protein synthesis,
EPO did not further activate AKT signaling or MAPK signaling
following exercise. In human skeletal muscle at rest, an acute
systemic injection of 400 IU/kg EPO did not alter the baseline
phosphorylation levels of AKT, MAPK, STAT5, and NFKB when
measured between 1 and 6 h following treatment (Christensen
et al., 2012a). We recently reported similar observations in
human primary muscle cells treated with EPO and proposed
that the EPOR is present, but may not be functional in human
muscle cells (Lamon et al., 2014). Still, EPO has shown effects
on skeletal muscle tissue, which may therefore not be via
the EPOR but via a surrogate muscle specific or non-specific
pathway. In healthy humans, 8 weeks of EPO treatment enhanced
muscle mitochondrial oxidative phosphorylation and maximal
electron transport capacity (Plenge et al., 2012). This outcome
is in line with observations made in earlier rodent studies
(Cayla et al., 2008; Hojman et al., 2009) but may result from
hyperoxia augmenting muscle oxidative capacity (Ploutz-Snyder
et al., 1996), rather than from a direct effect of EPO in muscle.
EPO administration increased whole-body energy expenditure
(Christensen et al., 2012b) and it was recently suggested that the
mechanism may be via an increase in UCP2 mRNA levels in
muscle (Christensen et al., 2013). Finally, several studies suggest
that EPO plays a role in skeletal muscle regeneration in humans.
A recent study reported that in human muscle tissue, EPO may
assist in stimulating the myogenic fate in satellite cells (Hoedt
et al., 2015). In addition, patients suffering Friedrich ataxia
displayed improved motor function when treated with EPO
(Nachbauer et al., 2012). A role for EPO in improving muscle
regeneration and strength following different types of injuries has
also been reported in different rodent studies (Kao et al., 2007;
Rotter et al., 2008, 2012; Jia et al., 2012). Altogether, these results
suggest that the effects of acute or chronic EPO injection on
human skeletal muscle may not be exerted by a direct activation
of the EPOR, but rather be the consequence of an enhanced
oxygen carrying capacity of the blood. Alternatively, there might
be a need to investigate models displaying supra-physiological
EPO concentrations (Hojman et al., 2009) or extreme metabolic
challenges (Nachbauer et al., 2012) to observe an activation of the
EPO-R in skeletal muscle.
Our study is the first one to examine the combined effects
of EPO and exercise on muscle protein synthesis and to
assess these effects in young and older subjects. State-of-the art
radiolabelled tracer technology was used to investigate protein
synthesis in vivo and further confirmed time discrepancies
between the activation of the markers of protein synthesis
and the actual functional outcome. While both parameters
are contingent, caution should be taken when only reporting
changes in marker expression. As it is often the case in
human exercise trials, one important limitation of our study is
the difference existing between the studied population cohort
and the age-matched average population cohort in terms of
physiological characteristics and level of fitness. It is commonly
acknowledged that the older subjects recruited on a voluntary
basis for an exercise trial protocol are not representative of
the average elderly population and that their average level
of fitness is expected to be higher. This parameter therefore
needs to be considered when comparing our results to other
studies.
In conclusion, a single bout of resistance exercise activated
muscle protein synthesis signaling in young and old skeletal
muscle but an acute EPO injection had no synergistic effect on
muscle protein synthesis rates or on the activation of the muscle
protein synthesis signaling pathways. This suggests that EPO is
not able to activate AKT and MAPK signaling in young or older
human skeletal muscle. These results refute a potential anabolic
role of EPO in human skeletal muscle and contribute to calls to
limit its misuse as a doping agent.
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